Trial Profile
A Phase 1 Subject-Blinded, Placebo-Controlled Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Healthy Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs TAK 101 (Primary)
- Indications Coeliac disease
- Focus Adverse reactions
- 15 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Apr 2018 New trial record